Masked Immunotherapy: New Cancer Drug Shows Promise in Prostate Cancer Trials

Early results from a clinical trial suggest a new immunotherapy drug, VIR-5500, is showing promise in treating advanced prostate cancer, particularly in patients who have stopped responding to other treatments. The drug, a “masked T-cell engager,” aims to harness the body’s own immune system to fight the disease.

According to preliminary data presented at an oncology conference and reported by Vir Biotechnology on February 23, 2026, 82% of patients receiving the highest doses of VIR-5500 experienced reductions in prostate-specific antigen (PSA) levels, a key indicator of prostate cancer progression. Nearly half of those patients likewise exhibited tumor shrinkage, both at the primary tumor site and in areas where the cancer had metastasized, according to the company’s investor relations statement.

Immunotherapies have achieved significant success in treating various cancers in recent years, but prostate cancer has remained a particularly challenging target. T-cell engagers represent a specific approach within immunotherapy, functioning by physically linking T-cells – immune cells crucial for fighting cancer – with cancer cells themselves. This enforced proximity triggers the T-cells to release toxins and initiate inflammatory processes designed to destroy the cancer cells.

Currently, over 200 different T-cell engagers are under investigation in clinical trials for a range of cancers, including multiple myeloma, leukemia, and lung cancer. Beyond oncology, researchers are exploring their potential in treating viral conditions like hepatitis B, where the virus similarly evades immune responses.

A significant challenge with T-cell engagers, and some other immunotherapies, is the potential for triggering an excessive inflammatory response known as cytokine release syndrome. This condition, caused by the overproduction of cytokines – signaling proteins that regulate inflammation – can lead to multi-organ failure and life-threatening complications.

VIR-5500 employs a novel approach to mitigate this risk: “masking.” The drug is initially inactive, covered by a molecular “mask” that prevents it from engaging both T-cells and cancer cells. Once inside a tumor, molecules abundant in the cancer microenvironment break down this mask, activating the drug and allowing it to target cancer cells specifically. This tumor-specific activation aims to limit the inflammatory response to the tumor site, reducing systemic toxicity.

The masking strategy also offers potential advantages in drug delivery. The slower release of the active drug facilitated by the mask could simplify dosing regimens and extend the drug’s lifespan within the body. Importantly, the early trial data suggest the masking is effective. most patients receiving the highest doses of VIR-5500 experienced only mild inflammatory side effects.

Researchers believe that masked immunotherapies could be combined with traditional cancer treatments like chemotherapy or radiotherapy to enhance their effectiveness. Several other masked T-cell engagers are currently in early clinical trials for prostate cancer, as well as for pancreatic, colorectal, and lung cancers.

Further research, including peer-reviewed publications and larger-scale clinical trials, is needed to fully assess the safety and efficacy of VIR-5500 and other masked T-cell engagers.